AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$ACRV

Gamelin Erick sold $804 of ACRV

Gamelin Erick (Chief Development Officer) sold 400 shares of Acrivon Therapeutics, Inc. (ACRV) at $2.01 on 2026-08-18.

Original reporting
SEC EDGAR · Gamelin Erick
Published Aug 20, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ACRV
Neutral
high confidence
Mentioned
$ACRV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACRVNeutralLow
01

Why it matters

The sale is unlikely to affect ACRV's valuation; investors may monitor future insider activity.

02

Market read

Limited relevance; primarily of interest to shareholders tracking insider holdings.

03

What to watch

Potential upcoming dilution or financing activity not disclosed.

Relevance 3/10Novelty 3/10Timing: filing date 2026-08-20

Background

Form 4 filings disclose insider transactions; this is a routine sale by an executive.

Company-level read

Ticker impact

$ACRVNeutralHigh confidence
Context

Chief Development Officer sold 400 shares at $2.01, reducing his stake to 52,592 shares.

Expected impact

No material price impact expected.

Evidence & confidence

The transaction size ($804) is trivial for a public company and does not signal a change in outlook.

Market effects

Sector

None; the sale is company‑specific and does not affect the biotech sector.

Regional

None; no broader regional effect.

Global

None; limited to ACRV shareholders.

Counterpoint

What could challenge this read

Even small insider sells can precede negative news, but no evidence here.

Key entities

  • Person
    Gamelin Erick

    Chief Development Officer of Acrivon Therapeutics, Inc.

  • Company
    Acrivon Therapeutics, Inc.

    Biotech firm developing therapies; ticker ACRV.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ACRV insider trading history →

Related articles

$ACRVMedAI 8/10

Acrivon Therapeutics Highlights Phase 2-Ready ACR-525 and Preclinical EoE Programs

Acrivon Therapeutics presented its immunology and inflammation programs, including the Phase 2-ready ACR-525, a selective JAK1 inhibitor, and a preclinical PKCθ inhibitor program, at an R&D event. The company highlighted EoE's growing patient population and treatment gaps as rationale for ACR-525's development, citing favorable early clinical data and safety profile. The presentation is available on the company's investor website.

tradingview.com
$ACRVMedAI 8/10

Acrivon to present cancer drug trial data at November symposium

Acrivon Therapeutics (ACRV) will present Phase 1/2 trial data for ACR-2316 at a cancer symposium in November. The study showed clinical activity in endometrial and lung cancers, with one patient achieving complete response. The trial has progressed to dose expansion, including pancreatic cancer patients. ACRV uses its AP3 platform to predict patient responses.

investing.com
$ACRVMedAI 8/10

Acrivon advances CDK11 inhibitor for AML, targets 2027 IND filing

Acrivon Therapeutics (ACRV) announced the advancement of ACR-7280, an oral CDK11 inhibitor, as its next development candidate. The company plans to file an IND application for the drug with the FDA in the first half of 2027. ACR-7280 showed complete tumor regression in AML xenograft models and potential in combination therapies. Acrivon's lead program, ACR-368, is in a Phase 2 trial for endometrial cancer.

investing.com
$ACRVMed

Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

Acrivon Therapeutics, Inc. (ACRV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026 ACR-2316 P

SEC EDGAR 8-K